Brigitte Englahner is a seasoned Clinical Research Professional at Pfizer, currently serving as a Site Relationship Partner. In this pivotal role, she acts as the primary liaison between Pfizer and assigned investigative sites, ensuring seamless communication and collaboration throughout the lifecycle of clinical studies. With...
Brigitte Englahner is a seasoned Clinical Research Professional at Pfizer, currently serving as a Site Relationship Partner. In this pivotal role, she acts as the primary liaison between Pfizer and assigned investigative sites, ensuring seamless communication and collaboration throughout the lifecycle of clinical studies. With her extensive experience in global study management and clinical operations, Brigitte excels in building and nurturing relationships that are crucial for site activation and ongoing support. Her bilingual proficiency enhances her ability to connect with diverse stakeholders, fostering a culturally sensitive environment that promotes effective problem-solving.
Brigitte's expertise spans various therapeutic areas, including oncology and infectious diseases, where she has successfully managed complex clinical trials, particularly in Phase I studies. Her skills in vendor oversight and clinical quality assessments enable her to maintain high standards of compliance with Good Clinical Practice (GCP) guidelines, ensuring that all study documents are meticulously developed and reviewed. As a key player in data review processes, she prepares critical documents for interim analyses (IA) and clinical study reports (CSR), contributing to the integrity and reliability of clinical data.
In her role, Brigitte leverages her negotiation skills to facilitate productive interactions between Pfizer and investigative sites, addressing any challenges that arise with agility and professionalism. Her commitment to excellence in clinical research not only enhances site performance but also reinforces Pfizer's reputation as a leader in clinical development. Through her dedication and expertise, Brigitte Englahner continues to make significant contributions to the advancement of innovative therapies that improve patient outcomes.
